Impact of health policy on structural requisites for antimicrobial stewardship: A nationwide survey conducted in Japanese hospitals after enforcing the revised reimbursement system for antimicrobial stewardship programs

Affiliations

• ¹ The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Division of Infection Control Sciences, Department of Clinical Pharmacy, School of Pharmacy, Showa University, 1-4-5 Hatanodai, Shinagawa-ku, Tokyo, Japan. Electronic address: [email protected].
• ² The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, Kyoto, Japan.
• ³ The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Department of Pharmacy, Kyoto Prefectural University of Medicine, Kyoto, Japan.
• ⁴ The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Department of Pharmacotherapy, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Hokkaido, Japan.
• ⁵ The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Department of Infectious Disease and Hospital Epidemiology, Saga University Hospital, Saga, Japan.
• ⁶ The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Department of Infection Control and Laboratory Diagnostics, Tohoku University Graduate School of Medicine, Miyagi, Japan.
• ⁷ The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Division of Infectious Diseases and Infection Control, Tohoku Medical and Pharmaceutical University Hospital, Miyagi, Japan.
• ⁸ The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Department of Internal Medicine, Niigata Prefectural Shibata Hospital, Niigata, Japan.
• ⁹ The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Division of Infection Control & Laboratory Medicine University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.
• ¹⁰ The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Division of Clinical Infectious Diseases, Department of Medicine, School of Medicine, Showa University, Tokyo, Japan.
• ¹¹ The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
• ¹² The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
• ¹³ The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Division of Infection Control and Prevention, Department of Medical Safety Management, Kindai University Hospital, Osaka, Japan.
• ¹⁴ The Antimicrobial Stewardship Committee of Japanese Society of Chemotherapy, Japan; Department of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan.